A large cohort study found that only a small percentage of teens received proper aftercare following near-fatal overdoses. Alinsky and colleagues1 examined data from over 4 million Medicaid enrollees (N = 4,039,216) and found only 1 in 54 youths aged 13 to 22 years received evidence-based pharmacotherapy after an overdose (FDA approved medications come in the form of naltrexone, buprenorphine, or methadone). It is key to provide patients with swift and appropriate treatment within one month of a near overdose, but unfortunately this happens in very few cases. In this Q&A, lead author Rachel H. Alinsky, MD, MPH, Adolescent Medicine and Addiction Medicine Fellow at Johns Hopkins University School of Medicine provides key insights from the study.
Psychiatric Times (PT): Your research highlights the need for quality treatment, especially for younger patients. What other insights can you provide about interventions and obstacles to treatment?
Rachel H. Alinsky, MD, MPH (RHA): We need to find effective interventions that can link adolescents and young adults directly into treatment after an opioid overdose. We also need to evaluate what barriers exist to accessing care at the time of overdose (such as insurance restrictions, lack of community providers or treatment centers, stigma), and find strategies to mitigate these barriers. System-level changes will be necessary, such as targeted federal funding for research and treatment for youth, decreasing insurance barriers, and increasing the availability of youth-serving physicians and addiction treatment centers.
PT: The study observes, “Nonfatal opioid overdose may be a critical touch point when youths who have never received a diagnosis of opioid use disorder can be engaged in treatment.” Can you tell us more about that? What can you tell us about stigma and recovery?
RHA: In the addiction treatment field, we actually don’t abide by the old adage of people having to “hit rock bottom” before they are ready to get treatment. This is somewhat of a myth. What we are trying to emphasize in our article is that overdose is a particularly crucial time that we can draw someone into treatment because they are presenting into the medical setting, seeing doctors, and we have this opportunity to interact with them and offer them treatment. Coming into the emergency department with an overdose may be the only time this person is sitting face to face with a doctor, and we want to capitalize on this opportunity to offer the best care we can to the patient.
This does not mean they did not want treatment a month ago or a week ago—they very well might have wanted treatment but not known how to access it amidst a very difficult to navigate addiction treatment system. So, when the patient is physically with us after an overdose, we have the chance to help them gain access to this life-saving treatment that otherwise would have been hard for them to get.
PT: What key points derived from the study would you like psychiatrists to know? About addiction? About opioids? About younger patients?
RHA: Prior to this study, we knew that teens and young adults were about one-tenth as likely as adults to receive treatment for opioid use disorder in general.2 And while we knew that over 4000 adolescents and young adults between the ages of 15 to 24 die from an opioid overdose every year,3 very little was known about health care use following nonfatal opioid overdose in youth. We were interested in figuring out the extent to which adolescents and young adults are receiving evidence-based treatment after a nonfatal opioid overdose.
We found that less than less than 1 in 50 adolescents and young adults who had an opioid overdose received the standard of care medication treatment that is recommended by the American Academy of Pediatrics.4 We also found that youth with opioid overdose have a high risk of recurrent overdose, as over 8% of youth with heroin overdose experience another overdose within three months.1
When an adolescent or young adult goes to the hospital with an emergency—you expect them to get the treatment they need. But here we see that less than 2% are getting that treatment, which would not be acceptable for any other medical condition. In pediatrics, we would not accept it if only 1 in 50 youth with asthma got the standard treatment when they came into the emergency department, or if 1 in 50 youth with diabetes got the standard treatment if they were hospitalized with diabetic ketoacidosis. Pediatricians just wouldn’t find that treatment gap acceptable. Yet this is where are now with the treatment our system is able to provide to youth who have an opioid overdose—and we need to do better for them.
Additionally, the high rates of recurrent overdose that we found mean that it is all the more important to get these youth into effective treatment as soon as possible to try to prevent another overdose. It is important to note that prescribing practices be closely monitored in young people, a critically neglected patient population when it comes to addiction monitoring. As verified in an earlier study of 2,752,612 adolescents: “Safe opioid prescribing practices are critical to mitigate the risk of prescription opioid overdose in adolescents and young adults.”5
PT: What symptoms do younger patients often present that clinicians might miss?
RHA: In the case of youth who are presenting with opioid overdose—this is not a subtle finding that one might miss. There is a chance, however, that clinicians may view this as a standalone incident, and not recognize it as a manifestation of an adolescent’s underlying opioid use disorder. Thus, clinicians should be thinking about and evaluating for opioid use disorder in any youth that is presenting with an overdose, by probing for criteria such as taking the opioid in larger amounts than intended, unsuccessful efforts to cut down, cravings, recurrent use despite failure to fulfill obligations at school or home, or recurrent use in physically hazardous situations.
1. Alinsky RH, Zima BT, Rodean J, et al. Receipt of Addiction Treatment After Opioid Overdose Among Medicaid-Enrolled Adolescents and Young Adults. JAMA Pediatr. 2020 Jan 6:e195183. [Epub ahead of print].
2. Chua K-P, Brummett CM, Conti RM, et al. Association of Opioid Prescribing Patterns With Prescription Opioid Overdose in Adolescents and Young Adults. JAMA Pediatr. December 16, 2019. doi:10.1001/jamapediatrics.2019.4878.
3. National Institute on Drug Abuse. Overdose Death Rates. https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates. Revised January 2019. Accessed January 14, 2020.
4. Committee on Substance Use and Prevention. Medication-assisted treatment of adolescents with opioid use disorders. Pediatrics. 2016;138:e20161893-e20161893.
5. Feder KA, Krawczyk N, Saloner B. Medication-assisted treatment for adolescents in specialty treatment for opioid use disorder. J Adolesc Health. 2017;60:747-750.
6. Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal
opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169:137-145.
7. National Academies. Medications for Opioid Use Disorder Save Lives. March 20, 2019. http://www.nationalacademies.org/hmd/Reports/2019/medications-for-opioid-use-disorder-save-lives.aspx. Accessed January 14, 2020.
8. Hadland SE, Bagley SM, Rodean J, Silverstein M, et al. Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder. JAMA Pediatr. 2018;172:1029-1037.
9. D’Onofrio G, O’Connor PG, Pantalon MV, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313:1636-1644.